Acción 1ZL ZAI LAB LIMITED
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate

Otros idiomas Zai Lab Limited Deutsche Boerse AG

Acciones

1ZL

US98887Q1040

Mercado cerrado - Deutsche Boerse AG
Otros sitios de cotización
 08:09:11 02/07/2024 		Varia. Cinco días. Varia. 1 de enero.
15,7 EUR -0,63 % Gráfico intradía de Zai Lab Limited -7,10 % -35,66 %
27/06 Un iniciado de Zai Lab vendió acciones por valor de 428.532 dólares, según un reciente registro de la SEC MT
20/06 Zai Lab concede ADS a directores independientes en virtud de un plan de incentivos MT

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias: ¡Sea el primero en enterarse y reaccione antes que los mercados!
Inscripción 100% Gratuita
Zai Lab Insider Sold Shares Worth $428,532, According to a Recent SEC Filing
Zai Lab : Argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropath
Zai Lab Grants ADSs to Independent Directors Under Incentive Scheme
Asian Equities Traded in the US as American Depositary Receipts Trend Lower in Friday Trading
Zai Lab Limited Announces Executive Changes, Effective June 30, 2024
Zai Lab Announces Dr. Harald Reinhart to Retire as Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases; Dr. Rafael Amado to be Appointed President, Head of Global R&D
Tech, Financial Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Sharply Lower Tuesday
Asian Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading, End Week Lower
Zai Lab Doses First Patient in a Phase 2 Clinical Trial of Plaque Psoriasis Treatment; Shares Rise
Zai Lab Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis
Zai Lab Limited Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis
Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China
Chinese Regulator Approves Zai Lab’s New Drug Application for Bacterial Pneumonia Drug
Zai Lab, Innoviva Subsidiary Receive China Approval for Hospital Infection Treatment
Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China
Zai Lab and Innoviva Specialty Therapeutics Announces NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China
Asian Equities Traded in the US as American Depositary Receipts Ease in Thursday Trading
Zai Lab Announces Participation in May and June Investor Conferences
Zai Lab's Supplemental Application for Autoimmune Disease Treatment Accepted by China Regulator
Zai Lab Announces Acceptance of Supplemental Biologics License Application with Priority Review for Efgartigimod Alfa Injection (Subcutaneous Injection) in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción ZLAB
  4. Acción 1ZL
  5. Noticias Zai Lab Limited
  6. Otros idiomas